• Quest PharmaTech Inc., of Edmonton, Alberta, received a notice of allowance for a patent, titled "Combination Therapy for Treating Disease." It covers the use of monoclonal antibodies capable of targeting tumor antigens CA 125, MUC1, CA 19.9, TAG-72 and prostate-specific antigen.

• Silence Therapeutics plc, of London, received a notice of allowance for a patent directed to the technology involved in AtuPLEX, one of its small interfering RNA delivery systems. It specifically relates to AtuFect, the lipid that serves as the basis for the AtuPLEX delivery system, and covers the system incorporated in lead compound Atu027 and other RNAi candidates.

• Vermillion Inc., of Austin, Texas, received a notice of allowance for a patent, titled "Biomarkers for Peripheral Artery Disease." It covers the biomarker alpha1beta glycoprotein and biomarker combinations that include alpha1beta glycoprotein for diagnosis of PAD.